News
05-30-2013, 06:10 AM
Oncothyreon Inc. and Array BioPharma Inc. today announced that they will collaborate to develop and commercialize ARRY-380, an orally active, reversible and selective small-molecule HER2 inhibitor.
More... (http://www.news-medical.net/news/20130530/Oncothyreon-Array-BioPharma-to-develop-and-commercialize-ARRY-380-for-breast-cancer-patients.aspx)
More... (http://www.news-medical.net/news/20130530/Oncothyreon-Array-BioPharma-to-develop-and-commercialize-ARRY-380-for-breast-cancer-patients.aspx)